Sulfonylurea Compound

PHILADELPHIA — Among older adults with type 2 diabetes and chronic HF, treatment with the SGLT2 inhibitor canagliflozin was not associated with a reduction in median N-terminal pro-B-type natriuretic peptide levels compared with the sulfonylurea glimepiride, according to data presented at the American Heart Association Scientific Sessions.

A cohort of veterans with type 2 diabetes and reduced kidney function prescribed metformin monotherapy were less likely to experience a major adverse cardiovascular event during 4 years of follow-up when compared with similar adults prescribed sulfonylurea therapy, according to findings published in JAMA.